Vor Biopharma (NYSE:VOR) Shares Down 5.6% - What's Next?

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) traded down 5.6% during trading on Monday . The company traded as low as $1.29 and last traded at $1.34. 449,903 shares changed hands during trading, a decline of 45% from the average session volume of 817,967 shares. The stock had previously closed at $1.42.

Analysts Set New Price Targets

VOR has been the subject of several research analyst reports. JMP Securities reiterated a "market outperform" rating and issued a $12.00 price objective on shares of Vor Biopharma in a research report on Tuesday, December 10th. Wedbush restated an "outperform" rating and issued a $11.00 price objective on shares of Vor Biopharma in a report on Monday, December 9th. Robert W. Baird lowered their target price on shares of Vor Biopharma from $22.00 to $14.00 and set an "outperform" rating for the company in a report on Friday, November 8th. Finally, HC Wainwright reissued a "buy" rating and issued a $17.50 price target on shares of Vor Biopharma in a research note on Tuesday, December 10th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $11.36.

Vor Biopharma Stock Down 6.0 %

The company's fifty day simple moving average is $1.21 and its two-hundred day simple moving average is $0.97. The company has a market capitalization of $96.82 million, a price-to-earnings ratio of -0.85 and a beta of -0.45.

Vor Biopharma (NYSE:VOR - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.40) earnings per share for the quarter, meeting the consensus estimate of ($0.40). Equities research analysts expect that Vor Biopharma Inc. will post -1.42 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Cubist Systematic Strategies LLC acquired a new stake in shares of Vor Biopharma in the second quarter valued at approximately $53,000. Rosalind Advisors Inc. acquired a new position in Vor Biopharma during the third quarter valued at approximately $54,000. Exchange Traded Concepts LLC grew its stake in Vor Biopharma by 40.8% in the third quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company's stock valued at $116,000 after purchasing an additional 48,017 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Vor Biopharma by 48.0% during the 2nd quarter. Renaissance Technologies LLC now owns 495,300 shares of the company's stock worth $495,000 after purchasing an additional 160,642 shares during the last quarter. 97.29% of the stock is currently owned by institutional investors.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.